Researchers found that the factors most associated with health related quality of life (HRQOL) in patients with facial palsy are age, bilateral facial palsy, severity of facial palsy, anxiety, and key personality traits, including extraversion and emotional stability.
Researchers found that the factors most associated with health related quality of life (HRQOL) in patients with facial palsy are age, bilateral facial palsy, severity of facial palsy, anxiety, and key personality traits, including extraversion and emotional stability.
“This study provides insight into factors that are important when measuring HRQOL in patients with facial palsy,” the researchers said.
Additional factors examined in the study included duration of facial palsy, cause, marital status, education level, occupational status, monthly income, and 5 personality traits (extraversion, agreeableness, conscientiousness, emotional stability, and openness to experiences). The study also looked at religious involvement and depression.
The 3 scales used to evaluate HRQOL in patients were the Facial Clinometric Evaluation (FaCE) Scale, the Facial Disability Index (FDI), and the Sunnybrook Facial Grading System. The FaCE and FDI scales are reported by patients with facial palsy, whereas the Sunnybrook Facial Grading System relies on clinician evaluations. The FDI is based on 2 aspects: social and physical function.
Although the Sunnybrook Facial Grading System was found to be associated with FDI physical scores, it was not found to be associated with FDI social scores. This suggests that a “distortion of the face as objectively graded by a clinician is less important than personality traits and unilateral or bilateral facial palsy when it comes to social function.”
The study supported the findings of another systematic review which found that personality traits characterized by positive affectivity, such as extraversion and emotional stability, were associated with higher HRQOL scores. Findings suggest that those with positive affectivity traits have more effective coping strategies.
No personality traits were found to be associated with FDI physical scores but 4 out of 5 of the traits assessed were associated with FDI social scores. This suggests that personality alters social consequences but not the perception of facial function.
Bilateral facial palsy was found to be negatively associated with FDI social scores. Researchers explained that those with bilateral facial palsy have a greater social disability due to the inability to express emotions by means of facial expression.
However, “perceived disability mainly depends on patients’ expectations and perceived control regarding the course of their condition,” the researchers noted.
Anxiety was found to alter the overall HRQOL but not specifically physical or social function. Depression was only found to be associated with FDI social scores.
Researchers suggest that, “it may be beneficial for patients when the clinician considers these factors in discussing facial palsy treatment because mental distress and personality traits are often overlooked.
Certain socioeconomic factors like age and facial function were found to be HRQOL predictors in previous studies. Although those findings were not supported in the new study, reasoning for this could be sample variation between the studies or the lack of skin elasticity for the elderly which can cause asymmetry in facial function.
Researchers noted “it is important to take these, and other factors identified in this study, into account in future research and treatment of patients with facial palsy.”
Reference
Bruins TE, van Veen MM, Mooibroek-Leeuwerke T, Werker PMN, Broekstra DC, Dijkstra PU. Association of socioeconomic, personality, and mental health factors with health-related quality of life in patients with facial palsy [published online February 13, 2020]. JAMA. doi: 10.1001/jamaoto.2019.4559.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More